
Journal of the American Chemical Society p. 3220 - 3230 (1994)
Update date:2022-08-05
Topics:
Jackson, Sharon
DeGrado, William
Dwivedi, Anil
Parthasarathy, Anju
Higley, Anne
Krywko, James
Rockwell, Arlene
Markwalder, Jay
Wells, Greg
Wexler, Ruth
Mousa, Shaker
Harlow, Richard
Although peptides adopt a large ensemble of conformations in aqueous solution, they are generally believed to bind to a receptor in a unique conformation. Thus, there is considerable interest in devising methods to restrict the conformational freedom of peptides. One such approach involves tying the amino and carboxy terminal ends of the peptide onto a semirigid template that will lock the intervening peptide backbone into a single conformer or a family of related conformers. This general strategy has been tested using the tripeptide sequence Arg-Gly-Asp (RGD), which binds with low affinity to the platelet glycoprotein IIb/IIIa (GPIIb/IIIa or α(IIb)β3). Mimics of RGD are of interest as antithrombotics because of their ability to inhibit the aggregation of platelets. Prior to this study, other workers (Samanen et al. J. Med. Chem. 1991, 34, 3114-3125) prepared a disulfide- containing cyclic pentapeptide that bound to GPIIb/IIIa with an affinity of approximately 0.1 μM. NMR analysis of the solution conformation of this peptide suggested that replacing the disulfide-containing portion of the cycle with the amino acid m-(aminomethyl)benzoic acid would lead to a more rigid structure. Indeed, introduction of this template into a cyclic RGD- containing peptide resulted in compounds with high affinity for the receptor. Further, systematic inclusion of additional conformational constraints in the form of N(α)- and C(α)-alkyl groups led to a peptide with an affinity of approximately 100 pM for binding to the receptor. This peptide also showed good activity in the platelet aggregation assay at oral doses as low as 0.1 mg/kg.
View MoreShaanxi King Stone Enterprise Company Limited
Contact:86-29-88353805,13609285751
Address:.209 Keji Road Hi-Tech industrial Develpment Zone .Xian China
Suzhou Chiral Pharmaceuticals Co., Ltd.
Contact:86-0512-63197058
Address:Building A, No. 2358, Chang'an Road, Wujiang Science Park
website:http://www.synchemie.com/
Contact:+86-574-87642758
Address:Room 901, Yinyi Bund Building, 132 Renmin Road
Shenzhen ZheYi Chemicals Co.,LTD(Shanghai Branch)
Contact:+86-21-54159691
Address:Room1002,Building No.2, Lane 98 Bixiu Road,Minhang District, Shanghai,China 201100
TIANJIN GST CHEMICAL TECHNOLOGY CO., LTD
Contact:+86-22-25210964
Address:Room. 208, No. -12-C, No. 13, Xinbei Road, Tanggu District, New Haixin Area, Tianjin City, China
Doi:10.1021/ol403688t
(2014)Doi:10.1002/chem.201303364
(2014)Doi:10.1021/jo01267a055
(1968)Doi:10.1039/DT9930003111
(1993)Doi:10.1016/S0040-4020(01)89978-6
(1987)Doi:10.1007/BF00531556
(1993)